Alsactide
{{short description|Chemical compound}}
{{EngvarB|date=July 2022}}
{{Use dmy dates|date=July 2022}}
{{Drugbox
| verifiedrevid = 448187817
| IUPAC_name =
| image = Alsactide.png
| width = 250px
| tradename =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 34765-96-3
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = J0K70H3420
| ATC_prefix = V04
| ATC_suffix = CH04
| PubChem = 16129705
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07417
| ChemSpiderID = 17286506
| C=99 | H=155 | N=29 | O=21 | S=1
| smiles = [H]/N=C(\N)/NCCC[C@@H](C(=O)N[C@@H](Cc1c[nH]c2c1cccc2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCCCCN)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc5cnc[nH]5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](Cc6ccc(cc6)O)NC(=O)CCN
| StdInChI = 1S/C99H155N29O21S/c1-59(2)84(97(148)113-56-81(132)115-68(26-10-14-40-101)87(138)119-69(27-11-15-41-102)88(139)118-67(25-9-13-39-100)85(136)109-45-18-17-43-104)127-96(147)79-30-20-47-128(79)98(149)73(28-12-16-42-103)116-82(133)55-112-86(137)76(51-62-53-111-66-24-8-7-23-65(62)66)124-89(140)70(29-19-46-110-99(106)107)120-93(144)75(49-60-21-5-4-6-22-60)123-94(145)77(52-63-54-108-58-114-63)125-90(141)71(35-36-83(134)135)121-91(142)72(38-48-150-3)122-95(146)78(57-129)126-92(143)74(117-80(131)37-44-105)50-61-31-33-64(130)34-32-61/h4-8,21-24,31-34,53-54,58-59,67-79,84,111,129-130H,9-20,25-30,35-52,55-57,100-105H2,1-3H3,(H,108,114)(H,109,136)(H,112,137)(H,113,148)(H,115,132)(H,116,133)(H,117,131)(H,118,139)(H,119,138)(H,120,144)(H,121,142)(H,122,146)(H,123,145)(H,124,140)(H,125,141)(H,126,143)(H,127,147)(H,134,135)(H4,106,107,110)/t67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,84-/m0/s1
| StdInChIKey = DIDCGVRALANKIU-OTEFFYEFSA-N
}}
Alsactide (INN; brand name Synchrodyn 1-17 or simply Synchrodyn; former development code Hoechst 433; also known as alisactide) is a synthetic peptide and analogue of adrenocorticotropic hormone (ACTH) which is used in Italy as a diagnostic agent in kidney function for adrenal insufficiency.{{cite book | vauthors = Elks J |title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA34|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=34–}}{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA33|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=33–}}{{cite book| vauthors = Morton IK, Hall JM |title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA12|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=12–}} Like ACTH, alsactide is thought to act as a non-selective agonist of the melanocortin receptors, including the ACTH receptor (MC2R).{{cite web | url = http://www.genome.jp/dbget-bin/www_bget?dr:D07417 | title = Alsactide | work = KEGG DRUG Database }} However, it appears to show a different profile of receptor selectivity relative to ACTH, as it apparently demonstrated no evidence of inhibition of endogenous ACTH in Addison's disease patients.{{cite book | vauthors = Kontogeorgos G |title=Molecular Pathology of the Pituitary|url=https://books.google.com/books?id=Atvixzf-d5wC&pg=PA66|date=1 January 2004|publisher=Karger Medical and Scientific Publishers|isbn=978-3-8055-7740-3|pages=66–}}
See also
References
{{Reflist|2}}
{{Diagnostic agents}}
{{Melanocortin receptor modulators}}